Budesonide 1 mg compresse orodispersibili ( DrugBank: Budesonide )


1 disease
IDDisease name (Link within this page)Number of trials
98Eosinophilic gastrointestinal disease1

98. Eosinophilic gastrointestinal disease


Clinical trials : 171 Drugs : 184 - (DrugBank : 47) / Drug target genes : 42 - Drug target pathways : 141
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2017-003516-39-IT
(EUCTR)
09/07/202117/08/2021A phase III clinical study in adult and adolescent patients with eosinophilic inflammation of the gullet to prove superiority compared to placebo of an episodic and/or a continuous 48-week treatment with budesonide orodispersible tablets for maintaining remissionDouble-blind, randomized phase III trial in adult and adolescent patients with eosinophilic esophagitis to prove superiority compared to placebo of an episodic and/or a continuous 48-week treatment with budesonide orodispersible tablets for maintaining clinico-histological remission - Episodic and continuous treatment with budesonide orodispersible tablets versus placebo for maintena Maintenance of remission in eosinophilic esophagitis
MedDRA version: 20.1;Level: LLT;Classification code 10064220;Term: Eosinophilic esophagitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Trade Name: Jorveza 1 mg compresse orodispersibili
Product Name: Budesonide 1 mg compresse orodispersibili
Product Code: [BUL 1 mg]
INN or Proposed INN: BUDESONIDE
Trade Name: Jorveza 0.5 mg compresse orodispersibili
Product Name: Budesonide 0.5 mg compresse orodispersibili
Product Code: [BUL 0.5 mg]
INN or Proposed INN: BUDESONIDE
DR. FALK PHARMA GMBHNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
110Phase 3Spain;Germany;Switzerland;Italy